What is the appropriate management for a 30-year-old man with total cholesterol 211 mg/dL, high‑density lipoprotein (HDL) 57 mg/dL, triglycerides 227 mg/dL, and hemoglobin A1c (HbA1c) 5.8%?

Management of Dyslipidemia and Prediabetes in a 30-Year-Old Man

This 30-year-old man requires aggressive lifestyle modification as first-line therapy, with calculated LDL-C of 108 mg/dL (using Friedewald equation: 211 - 57 - 227/5 = 108) placing him below the threshold for immediate statin therapy, but his moderate hypertriglyceridemia (227 mg/dL) and prediabetes (HbA1c 5.8%) demand comprehensive risk factor management to prevent progression to diabetes and cardiovascular disease.

Immediate Priority: Calculate 10-Year ASCVD Risk

Before making pharmacotherapy decisions, you must calculate his 10-year ASCVD risk using the pooled cohort equations 1. This requires:

• Blood pressure measurement
• Smoking status
• Race/ethnicity

If his 10-year ASCVD risk is ≥7.5%, initiate moderate-intensity statin therapy after a clinician-patient risk discussion 1.

If his 10-year ASCVD risk is 5-7.5% (borderline), the presence of risk-enhancing factors would favor statin initiation 1. His risk-enhancing factors include:

• Persistent triglyceride elevation ≥175 mg/dL (he has 227 mg/dL)
• Prediabetes/metabolic syndrome features
• Family history of premature ASCVD (if present)

Triglyceride Management (227 mg/dL = Moderate Hypertriglyceridemia)

His triglycerides fall into the moderate hypertriglyceridemia category (175-499 mg/dL) 1. Address and treat lifestyle factors, secondary factors, and medications that increase triglycerides as Class I recommendation 1:

Lifestyle Interventions (Mandatory First Step):

• Dietary modifications: Reduce refined carbohydrates and simple sugars, limit saturated fat, avoid alcohol
• Weight reduction: If BMI >25 kg/m² (calculate his BMI)
• Physical activity: At least 150 minutes/week of moderate-intensity exercise 2
• Omega-3 fatty acids: Consider supplementation for triglyceride reduction

Screen for Secondary Causes:

• Hypothyroidism (TSH)
• Chronic kidney disease (creatinine, eGFR)
• Chronic liver disease (hepatic panel)
• Review medications: thiazides, beta-blockers, oral estrogens, atypical antipsychotics, glucocorticoids 1

Pharmacotherapy Consideration:

After lifestyle modifications, if triglycerides remain persistently elevated ≥175 mg/dL and his 10-year ASCVD risk is ≥7.5%, it is reasonable to consider his elevated triglycerides as a factor favoring initiation or intensification of statin therapy 1. Statins provide dual benefit: LDL-C reduction and modest triglyceride lowering.

Prediabetes Management (HbA1c 5.8%)

His HbA1c of 5.8% indicates prediabetes (5.7-6.4% range). Intensive lifestyle modification is the cornerstone 2:

• Dietary counseling: Heart-healthy diet emphasizing whole grains, vegetables, lean proteins
• Physical activity: 150 minutes/week moderate-to-vigorous activity (Class I) 2
• Weight loss: 7% body weight reduction if overweight/obese
• Consider metformin: May be considered for diabetes prevention, particularly if BMI ≥35 kg/m², age <60 years, or history of gestational diabetes

The prediabetes increases his long-term cardiovascular risk and makes aggressive lifestyle intervention even more critical 3, 4.

HDL-C Assessment (57 mg/dL)

His HDL-C of 57 mg/dL is above the low threshold (<40 mg/dL for men), which is favorable. However, the combination of borderline-high triglycerides with relatively normal HDL suggests early metabolic dysfunction that responds well to lifestyle changes 5.

Clinical Pitfalls to Avoid

1. Don't ignore moderate hypertriglyceridemia: While not severe enough to cause pancreatitis risk, triglycerides of 227 mg/dL contribute to ASCVD risk through atherogenic VLDL particles 1, 5

2. Don't calculate LDL-C using Friedewald equation if triglycerides >400 mg/dL: His triglycerides are 227 mg/dL, so Friedewald is acceptable, yielding LDL-C ≈108 mg/dL

3. Don't start fibrates without first optimizing lifestyle and considering statin therapy: Fibrates are reserved for severe hypertriglyceridemia (≥500 mg/dL) or as add-on therapy 1

4. Don't miss the window for diabetes prevention: His HbA1c of 5.8% represents a critical intervention point where lifestyle changes can prevent progression to diabetes

Follow-Up Strategy

Reassess in 3 months after lifestyle interventions:

• Repeat fasting lipid panel
• Repeat HbA1c
• Assess weight, blood pressure, lifestyle adherence
• Recalculate ASCVD risk if not done initially

If triglycerides remain ≥175 mg/dL and/or ASCVD risk warrants treatment, initiate moderate-intensity statin therapy (e.g., atorvastatin 10-20 mg or rosuvastatin 5-10 mg) 1.

Monitor response 4-12 weeks after statin initiation with repeat lipid panel to assess adherence and percentage LDL-C reduction 1.